Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 7/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937018 | 1.00 | IRAK4 (0.40) | IRAK4SYKCHEK1MAPKAPK2KIT | |
| SCHEMBL1937750 | 0.83 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL1937748 | 0.83 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL1937724 | 0.82 | SYK (0.38) | SYKKITFLT3MAPK8MAPK9 | |
| SCHEMBL1937722 | 0.82 | SYK (0.38) | SYKKITFLT3MAPK8MAPK9 | |
| SCHEMBL1937691 | 0.81 | HCAR3 (0.54) | SYKHCAR3 | |
| SCHEMBL1937694 | 0.81 | HCAR3 (0.54) | SYKHCAR3 | |
| SCHEMBL13463627 | 0.80 | KIT (0.41) | IRAK4SYKCHEK1MAPKAPK2KIT | |
| SCHEMBL3623064 | 0.79 | SYK (0.41) | IRAK4SYKCHEK1MAPKAPK2MAPK8 | |
| SCHEMBL3623068 | 0.79 | SYK (0.41) | IRAK4SYKCHEK1MAPKAPK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | IRAK4 1074/4885SYK 1152/4885CHEK1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.